WATER IV PCa (AS Sub-study)
WATER IV Prostate Cancer: Aquablation Versus Active Surveillance for the Treatment of Localized Prostate Cancer
The WATER IV study is a multicenter, prospective, randomized clinical trial that aims to evaluate the safety and efficacy of Aquablation therapy in men with localized prostate cancer.
研究概览
详细说明
The WATER IV AS sub-study is a multicenter, prospective, randomized clinical trial that aims to evaluate the safety and efficacy of Aquablation therapy in men with low to intermediate risk localized prostate cancer who are candidates for active surveillance. Participants will be randomized to either Aquablation Therapy or active surveillance and followed up to 10 years.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Angela Lee
- 电话号码:650-232-7215
- 邮箱:a.lee@procept-biorobotics.com
学习地点
-
-
Arizona
-
Chandler、Arizona、美国、85224
- 尚未招聘
- Arizona State Urological Institute
-
首席研究员:
- Pratik Patel, MD
-
接触:
- Dianna Baldanado
- 邮箱:dbaldonado@asuri.net
-
-
California
-
Los Angeles、California、美国、90089
- 招聘中
- University of Southern California
-
首席研究员:
- Inderbir Gill, MD
-
首席研究员:
- Mihir Desai, MD
-
接触:
- Ileana Aldana
- 电话号码:(323) 865-0702
- 邮箱:Nohely.Aldana@med.usc.edu
-
Murrieta、California、美国、92562
- 尚未招聘
- Tri Valley Urology
-
接触:
- Anita Deeds
- 电话号码:232 951-698-1901
- 邮箱:anita@trivalleyurology.net
-
-
Colorado
-
Boulder、Colorado、美国、80304
- 尚未招聘
- Boulder Medical Center
-
接触:
- Stephanie Leonard
- 邮箱:sleonard@westernstatesncorp.org
-
-
Florida
-
Delray Beach、Florida、美国、33484
- 招聘中
- Advanced Research
-
首席研究员:
- Christopher Tallman, MD
-
接触:
- Julia Conceição
- 电话号码:(954)-302-3163
- 邮箱:jconceicao@advancedresearchfl.com
-
Miami、Florida、美国、33146
- 尚未招聘
- University of Miami
-
首席研究员:
- Bruno Nahar, MD
-
接触:
- Laura Ochoa
- 邮箱:lxo315@med.miami.edu
-
Tampa、Florida、美国、33607
- 尚未招聘
- Trophy Point Urology
-
接触:
- Zachary Finley
- 邮箱:zfinley@floridaurologypartners.com
-
首席研究员:
- Timothy Weber, MD
-
副研究员:
- Jonathan Pavlinec, MD
-
副研究员:
- David Hochberg, MD
-
副研究员:
- Drew Palmer, MD
-
副研究员:
- Sam Fisher, MD
-
-
Georgia
-
Atlanta、Georgia、美国、30328
- 招聘中
- Georgia Urology
-
首席研究员:
- Lewis Kriteman, MD
-
接触:
- Cyprian Adi
- 电话号码:404-292-3727
- 邮箱:Cyprian.adi@gaurology.com
-
副研究员:
- Froylan Gonzalez, MD
-
-
Idaho
-
Idaho Falls、Idaho、美国、83401
- 招聘中
- Mountain View Hospital
-
接触:
- Morgann Torres
- 邮箱:mtorres1@mvhospital.net
-
首席研究员:
- Jared Manwaring, MD
-
副研究员:
- Richard Blatter, MD
-
-
Illinois
-
Chicago、Illinois、美国、60637
- 尚未招聘
- University of Chicago
-
接触:
- Briana Harrison
- 邮箱:bharrison1@bsd.uchicago.edu
-
Glenview、Illinois、美国、60026
- 招聘中
- Endeavor Health
-
副研究员:
- Alexander Glaser, MD
-
接触:
- Pooja Talaty
- 邮箱:pooja.talaty@endeavorhealth.org
-
首席研究员:
- James Kearns, MD
-
副研究员:
- Brian Helfand, MD
-
-
Maryland
-
Baltimore、Maryland、美国、21287
- 尚未招聘
- Johns Hopkins University
-
首席研究员:
- Arun Rai, MD
-
接触:
- George Metri
- 邮箱:gmetri1@jh.edu
-
副研究员:
- Arvin George, MD
-
-
Missouri
-
North Kansas City、Missouri、美国、64116
- 尚未招聘
- Kansas City Urology Care
-
接触:
- Judy Searcy
- 电话号码:913-647-4173
- 邮箱:jsearcy@kcuc.com
-
首席研究员:
- Gerald Park, MD
-
副研究员:
- Patrick Probst, MD
-
-
Nebraska
-
Kearney、Nebraska、美国、68847
- 招聘中
- Kearney Urology Center
-
首席研究员:
- Garrett Pohlman, MD
-
接触:
- Monique Pohlman
- 邮箱:water4trialkearneyurology@gmail.com
-
Omaha、Nebraska、美国、68114
- 招聘中
- Adult & Pediatric Urology
-
首席研究员:
- Andrew Trainer, MD
-
接触:
- Christian Valverde
- 邮箱:cvalverde@urohealthpartners.com
-
-
New Jersey
-
Hackensack、New Jersey、美国、07601
- 尚未招聘
- Hackensack University Medical Center
-
首席研究员:
- Nitin Yerram, MD
-
接触:
- Oncology Clinical Research Referral Office
- 电话号码:551-996-1777
- 邮箱:OncologyResearchReferral@hmhn.org
-
副研究员:
- Ravi Munver, MD
-
-
New York
-
Albany、New York、美国、12208
- 尚未招聘
- Albany Medical College
-
首席研究员:
- Ronald Kaufman, MD
-
接触:
- Brenda Romeo
- 电话号码:(518) 262-8579
-
New York、New York、美国、10016
- 招聘中
- Integrated Medical Professionals, PLLC
-
首席研究员:
- Jed Kaminetsky, MD
-
首席研究员:
- Alexander Epelbaum, MD
-
首席研究员:
- Gary Goldberg, MD
-
接触:
- Michael Yang
- 邮箱:myang@imppllc.com
-
Rochester、New York、美国、14642
- 尚未招聘
- University of Rochester Medical Center
-
接触:
- Caitlyn Michelsen
- 邮箱:Caitlyn_Michelsen@URMC.Rochester.edu
-
首席研究员:
- Thomas Frye, MD
-
-
Ohio
-
Cleveland、Ohio、美国、44195
- 尚未招聘
- Cleveland Clinic Foundation
-
首席研究员:
- Petar Bajic, MD
-
接触:
- Lauren Grimm
- 电话号码:216-444-4650
- 邮箱:grimml@ccf.org
-
-
South Carolina
-
Charleston、South Carolina、美国、29425
- 招聘中
- MUSC Hollings Cancer Center
-
首席研究员:
- Eric Wallen, MD
-
接触:
- Sarah Helpinstill
- 电话号码:843-792-9300
- 邮箱:sah277@musc.edu
-
Murrells Inlet、South Carolina、美国、29576
- 尚未招聘
- Tidelands Health Urology
-
接触:
- Barbara Roe
- 邮箱:broe@tidelandshealth.org
-
首席研究员:
- Lauren Cooley, MD
-
-
Texas
-
Austin、Texas、美国、78745
- 招聘中
- Urology Austin
-
首席研究员:
- Brian Mazzarella, MD
-
接触:
- Jennifer Penshorn, RN
- 邮箱:jennifer.penshorn@urologyaustin.com
-
副研究员:
- David Cuellar, MD
-
副研究员:
- Eric Giesler, MD
-
副研究员:
- Varun Sundaram, MD
-
副研究员:
- Carl Bischoff, MD
-
Austin、Texas、美国、78705
- 招聘中
- Midtown Urology
-
接触:
- Andrew Barger
- 电话号码:512-451-7935
- 邮箱:APBarger@cimplify.net
-
首席研究员:
- Michael Trotter, MD
-
副研究员:
- Tyler McClintock, MD
-
Dallas、Texas、美国、75231
- 招聘中
- Urology Clinics of North Texas
-
首席研究员:
- Gregory Thoreson, MD
-
接触:
- Jacquelyn Ward
- 邮箱:jward@urologyclinics.com
-
-
Virginia
-
Alexandria、Virginia、美国、22311
- 尚未招聘
- Potomac Urology
-
首席研究员:
- Shawn Marhamati, MD
-
副研究员:
- Nilay Gandhi, MD
-
接触:
- Zoe Goldstein
- 邮箱:zoe.goldstein@potomacurology.com
-
-
Wisconsin
-
Sheboygan、Wisconsin、美国、53081
- 尚未招聘
- Advocate Aurora Research Institute
-
首席研究员:
- Jeffrey Tomasini, MD
-
接触:
- Mary Theodoroff
- 邮箱:mary.theodoroff@aah.org
-
-
-
-
-
Shatin、香港
- 尚未招聘
- Chinese University of Hong Kong
-
接触:
- Becky Lau
- 邮箱:beckylau@surgery.cuhk.edu.hk
-
首席研究员:
- Jeremy Teoh, MD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Biological male with age ≥ 45 years at the time of consent
- Biopsy positive Grade Group 2 prostate cancer or biopsy positive Grade Group 1 MRI visible lesion (PI-RADS/Likert ≥ 3)
- First prostate cancer diagnoses within 18 months (545 days) of consent
- Are candidates for active surveillance
- Clinical Stage ≤ T2c
- PSA < 15 ng/ml
- Prostate volume ≥25 ml
Exclusion Criteria:
- Any prior or current local or systemic treatment for prostate cancer, including but not limited to surgery, radiation therapy (external or brachytherapy), tissue ablation, hormone therapy or chemotherapy.
- Patients with previous surgical or minimally invasive treatment of benign prostatic hyperplasia within the prior 3 months of study treatment.
- Evidence of lymph node, bone metastasis, extracapsular extension or seminal vesicle invasion.
- Patient is unwilling to accept a blood transfusion if required.
- Any condition or history of illness or surgery that may pose an additional risk to patients undergoing the Aquablation or radical prostatectomy procedure such as:
5a. Medical conditions that preclude the use of anesthesia; 5b. Any condition or history of active rectal inflammatory bowel disease or other factors which might increase the risk of rectal injury (i.e. fistula formation); 5c. Patient is unable to stop anticoagulants or antiplatelet agents prior to study treatment per standard of care; 5d. Any other condition or history of infection, illness or surgery that in the opinion of the investigator might affect the outcome of the study procedure, study conduct, and study results; or pose additional risks to the patient (e.g., other cancer, active urethral stricture disease).
6. Patients who are unable to provide informed consent due to cognitive impairment, legal status (such as incarceration), or other factors limiting autonomy or unwilling or unable to follow study instructions including randomization and complete all required study visits through 10 years. This includes individuals with severe cognitive disabilities, those under legal guardianship, or those currently incarcerated.
7. Patient currently participating in other studies unless approved by Sponsor in writing.
8. More than one complete biopsy beyond the diagnostic biopsy comprising both a systematic biopsy and biopsy of any MRI visible lesion (PI-RADS/Likert ≥ 3).
9. GG2 disease with PSA ≥ 10 OR stage ≥ T2b OR ≥ 50% of biopsy cores positive (multiple cores taken from any MRI visible lesion are counted as one continuous core).
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Aquablation Therapy
The Aquablation Therapy arm will receive Aquablation with either the AQUABEAM Robotic System or HYDROS Robotic System |
The AquaBeam Robotic System and the HYDROS Robotic System utilize high-velocity sterile saline waterjet to resect prostate tissue, guided by real-time visualization through cystoscopy and transrectal ultrasound imaging. This minimally invasive surgical procedure is called the Aquablation therapy. |
|
有源比较器:Active Surveillance
The active surveillance arm will receive standard-of-care for prostate cancer management. |
Active surveillance is a management strategy for men with low- and favorable intermediate-risk localized prostate cancer that involves close monitoring with curative intent, reserving treatment for evidence of disease progression. Monitoring typically includes serial PSA testing, periodic prostate MRI, and repeat biopsies at scheduled intervals, with intervention triggered by evidence of disease progression. |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Freedom from GG ≥ 2
大体时间:12 Months
|
12 Months
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Freedom from persistent or increased MRI suspicion AND additional prostate cancer treatment
大体时间:3 Years
|
3 Years
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.